Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03779048 · ClinicalTrials.gov registry record · Phase 4
Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 147
- Enrollment target
NCT03779048: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT03779048 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 147 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03779048, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 147 participants
- Enrollment target
Study Summary
This is a two-phase study. Phase 1 will evaluate obesity-related behavioral and biological characteristics as potential predictors of response to behavioral treatment (BT) for weight loss. Phase 2 is a double-blind, placebo-controlled, RCT to test whether adding weight loss medication to BT improves 24-week weight loss, as compared to BT with placebo, in subjects identified as having suboptimal early weight loss after 4 weeks of individual behavioral weight control. All participants, regardless of their early weight loss, will receive the same BT program of diet, physical activity, and behavior therapy for weight loss for an additional 24 weeks (28 total weeks of treatment).
Interventions
- DRUG Placebo
- BEHAVIORAL Behavioral Treatment
- DRUG Phentermine 15 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2022-05-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03779048
The ClinicalTrials.gov registry entry for NCT03779048 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03779048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03779048 about?
NCT03779048 is a clinical study titled "Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment". This is a two-phase study. Phase 1 will evaluate obesity-related behavioral and biological characteristics as potential predictors of response to behavioral treatment (BT) for weight loss. Phase 2 is a double-blind, placebo-controlled, RCT to test whether adding weight loss medication to BT improves...
What is the current status of trial NCT03779048?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 147 participants. The study started on 2019-07-15. Estimated completion is 2022-05-25.
What interventions are being tested in trial NCT03779048?
The interventions under investigation include: Placebo (DRUG), Behavioral Treatment (BEHAVIORAL), Phentermine 15 MG (DRUG).
Who is sponsoring clinical trial NCT03779048?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.